42 results on '"Heim JM"'
Search Results
2. Digital flexion contractures secondary to tophaceous gout. A report of three cases
- Author
-
Caudle Rj, Heim Jm, and Peter J. Stern
- Subjects
musculoskeletal diseases ,Male ,medicine.medical_specialty ,Contracture ,Gout ,Flexor digitorum muscle ,Tophaceous gout ,Fingers ,Finger Joint ,medicine ,Humans ,Orthopedics and Sports Medicine ,Aged ,business.industry ,Tenosynovitis ,Middle Aged ,musculoskeletal system ,Tendon ,Surgery ,medicine.anatomical_structure ,Flexion contractures ,Upper limb ,medicine.symptom ,business - Abstract
This article presents three cases of gonty infiltration of the flexa tendons in the hand. Each presented with digital flexion contractures
- Published
- 1989
3. Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis.
- Author
-
Vasquez JG, Heim JM, Bhutani T, Koo J, Mathew J, Ferro T, and Bhatia N
- Abstract
Objective: Tildrakizumab, an anti-interleukin-23 p19 monoclonal antibody, is approved for the treatment of adults with moderate-to-severe plaque psoriasis. Limited evidence is available regarding the effects of tildrakizumab on patient-reported symptoms and satisfaction. This report describes the secondary endpoints of patient-reported symptoms and treatment satisfaction over 64 weeks in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab in a Phase IV, real-world study., Methods: In this uncontrolled, open-label study (NCT03718299), patients received tildrakizumab 100 mg at baseline, Week (W)4, and every 12 weeks thereafter to W52, with the final assessment at W64. Patient-reported secondary endpoints included numerical rating scale (NRS) scores for itch, pain, and scaling, and treatment satisfaction measured by 3 rating scales (Treatment Satisfaction Questionnaire for Medication [TSQM], Tildrakizumab Overall Satisfaction, and Patient Happiness with Psoriasis Control instrument) through W64., Results: Of the 55 patients enrolled, 45 were assessed at W64. Mean NRS scores for itch, pain, and scaling all decreased from baseline beginning as early as W4 with maintenance through W64 ( P ≤0.001). Treatment satisfaction was positive throughout treatment based on all 3 measures. Mean±SD TSQM domain scores increased from 59.5±17.0 at W4 to 79.5±20.1 at W64 for Effectiveness and from 72.7±18.6 to 81.9±20.5 for Global Satisfaction., Limitations: The study is small and lacks a comparator arm., Conclusion: Tildrakizumab treatment improved patient-reported symptoms in patients with moderate-to-severe plaque psoriasis in a real-world setting and was associated with high levels of treatment satisfaction over 64 weeks., Competing Interests: DISCLOSURES: Ms. Heim has been a speaker, adviser, and consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, and Novartis; an adviser for Galderma, Mayne Pharma, Regeneron Pharmaceuticals, and Sanofi; an adviser and consultant for Ortho Dermatologics; and a speaker and adviser for Beiersdorf, Incyte, LEO Pharma, and Sun Pharma. Dr. Bhutani has received research funding from AbbVie, Celgene, Eli Lilly, Galderma, Janssen, Pfizer, Regeneron Pharmaceuticals, and Sun Pharma; and has served as an adviser for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, LEO Pharma, and Novartis. Dr. Koo has served as an adviser for AbbVie, Amgen, Celgene, Eli Lilly, EPI Health, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and UCB. Drs. Mathew and Ferro are employees of Sun Pharmaceutical Industries, Inc. Dr. Bhatia is an adviser, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Advanced Derm Solutions, Amytrx, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle, Dermavant Sciences, Eli Lilly, Ferndale, Foamix, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Skinfix, Soligenix, Sun Pharma, Verrica Pharmaceuticals, and Zerigo Health. Dr. Vasquez reports no conflicts of interest relevant to the content of this article., (Copyright © 2024. Matrix Medical Communications. All rights reserved.)
- Published
- 2024
4. Upper limits on perturbations of nuclear decay rates induced by reactor electron antineutrinos.
- Author
-
Barnes VE, Bernstein DJ, Bryan CD, Cinko N, Deichert GG, Gruenwald JT, Heim JM, Kaplan HB, LaZur R, Neff D, Nistor JM, Sahelijo N, and Fischbach E
- Abstract
We report the results of an experiment conducted near the High Flux Isotope Reactor of Oak Ridge National Laboratory, designed to address the question of whether a flux of reactor-generated electron antineutrinos (ν¯
e ) can alter the rates of weak nuclear interaction induced decays of54 Mn,22 Na, and60 Co. This experiment has small statistical errors but, when systematic uncertainties are included, has null results. Perturbations greater than one part in 104 are excluded at 95% confidence level in β± decay and electron capture processes, in the presence of an antineutrino flux of 3 × 1012 cm-2 s-1 . The present experimental methods are applicable to a wide range of radionuclides. Improved sensitivity in future experiments can be anticipated as we continue to better understand and reduce the dominant systematic uncertainties., (Copyright © 2019. Published by Elsevier Ltd.)- Published
- 2019
- Full Text
- View/download PDF
5. Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine.
- Author
-
Gooden KM, Bibeau KB, Wood J, Irizarry MC, Pan X, Allen J, Sampson T, and Heim JM
- Subjects
- Adolescent, Adult, Aged, Cohort Studies, Databases, Factual, Drug Combinations, Endpoint Determination, Female, Humans, Incidence, Insurance, Health, Male, Middle Aged, Retrospective Studies, Risk Assessment, Young Adult, Antidepressive Agents, Second-Generation adverse effects, Diabetes Mellitus, Type 2 epidemiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Paroxetine adverse effects, Pravastatin adverse effects
- Abstract
Purpose: This study evaluated the effects of concomitant pravastatin and paroxetine use on the incidence of Type 2 Diabetes Mellitus (T2DM)., Methods: A new-user retrospective cohort design was employed using data selected from US health insurance claims databases (OptumInsight and MarketScan) between July 1, 2002, and December 31, 2009. Patients included were of age ≥18; newly prescribed pravastatin or paroxetine; and enrolled in the database for ≥180 days prior to the index date (i.e., first prescription of incident drug). Patients were assigned to either incident pravastatin or incident paroxetine user groups. Patients were followed until the study endpoint (T2DM), discontinuation of incident drug, second drug, or end of study/patient data. Cox proportional hazards models compared T2DM in users of pravastatin who were also taking paroxetine at index the date (combination users) versus pravastatinonly users. A similar analysis among users of paroxetine evaluated the use or non-use of pravastatin at index date., Results: OptumInsight yielded 288,678 incident users of pravastatin or paroxetine; 443,137 were identified in MarketScan. The risk of T2DM among combination users compared to incident pravastatin only users was 1.05 (95% CI: 0.76, 1.44) and 0.94 (95% CI: 0.90, 0.97) in OptumInsight and MarketScan, respectively. The risk of T2DM among combination users compared to incident paroxetine only users was 1.03 (95% CI: 0.69, 1.54) in OptumInsight and 1.02 (95% CI: 0.97, 1.07) in MarketScan., Conclusion: The results indicate no increase in the risk of T2DM due to combined use of pravastatin and paroxetine compared to individual use of the two drugs; however, this study is limited by short mean follow-up.
- Published
- 2015
- Full Text
- View/download PDF
6. Use of an algorithm for identifying hidden drug–drug interactions in adverse event reports.
- Author
-
Gooden KM, Pan X, Kawabata H, and Heim JM
- Subjects
- Humans, Adverse Drug Reaction Reporting Systems, Algorithms, Drug Interactions, Drug-Related Side Effects and Adverse Reactions diagnosis
- Published
- 2013
- Full Text
- View/download PDF
7. Oxidative stress and hemorheological changes induced by acute treadmill exercise.
- Author
-
Ajmani RS, Fleg JL, Demehin AA, Wright JG, O'Connor F, Heim JM, Tarien E, and Rifkind JM
- Subjects
- Adult, Aerobiosis, Aged, Aged, 80 and over, Blood Pressure, Blood Sedimentation, Blood Viscosity, Erythrocyte Aggregation physiology, Female, Fibrinogen metabolism, Heart Rate, Hematocrit, Hemoglobins metabolism, Humans, Lipid Peroxides blood, Male, Middle Aged, Oxygen blood, Reference Values, Exercise Test, Hemorheology, Oxidative Stress physiology
- Abstract
The present investigation was designed to evaluate the acute effect of aerobic exercise on oxidative stress and the flow properties of the blood. Fourteen clinically healthy subjects (7 men and 7 women aged 56+/-19 yr) underwent maximal treadmill exercise with blood samples drawn prior to and immediately after exercise. Post-exercise significant increases were observed in plasma lipid hydroperoxides from 6.5+/-2.0 microM to 7.9+/-1.9 microM (p<0.0001) and the relative concentration of plasma fluorescent products associated with red cell peroxidation from 138+/-28 RF to 220+/-92 RF (p<0.005). After exercise there was a rise in the hematocrit from 41.4+/-3.7% to 44.4+/-4.1% (p<0.0001), increases in whole blood viscosity at shear rates of 22.5/sec to 450/sec (p<0.0005), an increase in plasma viscosity from 1.27+/-0.12 cP to 1.36+/-0.11 cP (p<0.01), an increase in red cell rigidity from 2.44+/-0.48 cP to 2.62+/-0.42 cP (p<0.001) and a decrease in erythrocyte sedimentation rate from 26.9+/-18.6 mm/h to 22.5+/-15.9 mm/h (p<0.01). The findings suggest that acute aerobic exercise induces oxidative damage to red blood cells and adversely affects rheological properties of the peripheral blood.
- Published
- 2003
8. Particulate ANP-sensitive guanylyl cyclase in blood and bone marrow cells of patients with acute leukemia.
- Author
-
Knau B, Sturm C, Heim JM, Fricke H, Emmerich B, Haas R, and Gerzer R
- Subjects
- Acute Disease, Adult, Aged, Aged, 80 and over, Atrial Natriuretic Factor pharmacology, Child, Preschool, Cyclic GMP metabolism, Female, Humans, In Vitro Techniques, Leukocytes, Mononuclear enzymology, Male, Middle Aged, Bone Marrow enzymology, Guanylate Cyclase metabolism, Leukemia enzymology, Receptors, Atrial Natriuretic Factor metabolism
- Abstract
Increases in plasma cyclic GMP levels have been shown to correlate with increased plasma levels of atrial natriuretic peptide (ANP) in patients with fluid overload due to increased secretion of ANP. There is evidence that plasma cyclic GMP levels are also elevated in some patients with acute leukemia, but increased ANP secretion has not been demonstrated. To elucidate the possibility that a newly expressed guanylyl cyclase may be responsible for the increase of plasma cyclic GMP levels patients with acute and chronic leukemia as well as patients with lymphoma and healthy volunteers were studied. Plasma levels of cyclic GMP were measured and isolated peripheral blood mononuclear or bone marrow cells were incubated with increasing concentrations of ANP. The stimulation of cells was measured as cGMP accumulation in the supernatant. Furthermore guanylyl cyclase activity was measured in membrane preparations of peripheral blood mononuclear cells. While leukocytes of healthy subjects were devoid of detectable ANP-stimulated particulate guanylyl cyclase activity, ANP-sensitivity was observed in seven patients with acute lymphoblastic and in three patients with acute myelogenous leukemia. Cyclic GMP in the supernatant of cells was elevated between 2- and 132-fold of basal when cells were incubated with 1 microM ANP for 60 minutes. Like in healthy volunteers, no effect of ANP on freshly isolated mononuclear cells was observed in cases with chronic leukemia or in patients with lymphoma. Expression of ANP-sensitive particulate gunaylyl cyclase may be connected with malignant transformation of lymphocytes in patients with acute leukemia and might be useful for their diagnosis and classification.
- Published
- 1997
9. Particulate ANP-sensitive guanylyl cyclase: induction in cultured human peripheral CD3+ mononuclear blood cells.
- Author
-
Heim JM, Knau B, Sturm C, Fricke H, Hartmann J, Pachmann K, Schmidt KN, Vollmar A, and Gerzer R
- Subjects
- Animals, Cells, Cultured, Coculture Techniques, Cyclic GMP metabolism, Guanylate Cyclase genetics, Humans, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear drug effects, Polymerase Chain Reaction, Rats, Time Factors, Atrial Natriuretic Factor pharmacology, CD3 Complex, Guanylate Cyclase metabolism, Leukocytes, Mononuclear enzymology
- Abstract
There have been conflicting reports about the occurrence and/or activity of atrial natriuretic peptide (ANP) sensitive guanylyl cyclase in the immune system. This study reports on ANP-sensitive guanylyl cyclase mRNA expression and guanylyl cyclase activity in human peripheral blood mononuclear cells (PBMC). Reverse transcription polymerase chain reaction (RT-PCR) shows that activated human PBMC of healthy blood donors express functional active ANP-sensitive guanylyl cyclase after vitro culture, whereas freshly isolated PBMC show neither specific mRNA for particulate guanylyl cyclase nor ANP-sensitive activity of this enzyme. To define the subpopulation of PBMC expressing this enzyme, cultivated PBMC were subfractioned and analyzed by RT-PCR and in situ PCR. Only CD3+ PBMC showed mRNA for ANP-sensitive guanylyl cyclase. Induction of the guanylyl cyclase required coincubation with other cells, indicating that a factor or factors secreted from cells other than CD3+ cells induces this expression. In summary, ANP-sensitive guanylyl cyclase is an inducible enzyme in human CD3+ PBMC in contrast to other cells where it is considered to be constitutive.
- Published
- 1996
- Full Text
- View/download PDF
10. Effect of glycosylation on cloned ANF-sensitive guanylyl cyclase.
- Author
-
Heim JM, Singh S, and Gerzer R
- Subjects
- Animals, Cell Line, Cell Membrane enzymology, Cloning, Molecular, Glioma, Glycosylation, Guanylate Cyclase biosynthesis, Kinetics, Molecular Weight, Peptide Fragments pharmacology, Rats, Recombinant Proteins biosynthesis, Recombinant Proteins metabolism, Transfection, Tunicamycin pharmacology, Adrenal Cortex enzymology, Atrial Natriuretic Factor pharmacology, Guanylate Cyclase metabolism
- Abstract
Cloned ANF-sensitive guanylyl cyclase (GC-A) and ANF-sensitive guanylyl cyclase from adrenal cortex differ in their sensitivity to the ANF analogs atriopeptin 1 and urodilatin. To test the hypothesis that these differences are due to different glycosylation, we investigated the effect of the N-glycosylation inhibitor tunicamycin on GC-A. Tunicamycin altered the response of GC-A to atriopeptin 1 and urodilatin, whereas the sensitivity to ANF remained unchanged. These data indicate that agonist specificities of different ANF-sensitive guanylyl cyclases are influenced by carbohydrate moieties.
- Published
- 1996
- Full Text
- View/download PDF
11. Atrial-natriuretic-peptide receptors in glomerular cryosections of renal malignant and spontaneously hypertensive rats.
- Author
-
Marin-Grez M, Grigelat C, Heinz-Erian P, Heim JM, and Klein HG
- Subjects
- Animals, Atrial Natriuretic Factor chemistry, Atrial Natriuretic Factor pharmacology, Down-Regulation drug effects, Guanylate Cyclase metabolism, Hypertension genetics, Kidney Glomerulus drug effects, Kidney Glomerulus enzymology, Kinetics, Male, Natriuresis physiology, Radioimmunoassay, Rats, Rats, Inbred SHR, Rats, Sprague-Dawley, Atrial Natriuretic Factor metabolism, Hypertension metabolism, Hypertension, Malignant metabolism, Hypertension, Renovascular metabolism, Kidney Glomerulus metabolism, Receptors, Atrial Natriuretic Factor metabolism
- Abstract
ANP-receptors affinities (KD) and capacities (Bmax) were assayed in cryosections of glomeruli from 'malignant' hypertensive rats (2K-1C) and spontaneously hypertensive rats (PHR). Plasma ANP concentration was twofold higher in 2K-1C (P < 0.05) and PHR (P < 0.02) than in the respective controls, KD and Bmax for rANP99-126 and ANP103-123 did not differ. ANP mediated cGAMP release in 2K-1C rats was also unaffected. ANP-C glomerular receptors (i.e. displacement of tracer binding with ANP103-123) were not down-regulated and had unchanged peptide binding affinity in either kidney of rats with 'malignant' hypertension and in PHR. The difference between Bmax for rANP99-126 and Bmax for rANP103-123 (ANP-A receptor binding) indicates moderate up-regulation of ANP-A receptors in the clipped, and down-regulation in the contralateral kidney of 2K-1C (2K-1C, right vs. left, P < 0.05). Since [ANP]pl, and also Bmax and KD for ANP were similar in both hypertension models investigated, changes of the [ANP]pl/ANP-receptor system can not completely explain the marked natriuresis of rats with 'malignant' hypertension.
- Published
- 1995
- Full Text
- View/download PDF
12. A non-isotopic immunoassay for guanosine 3':5'-cyclic monophosphate using a cyclic GMP-biotin conjugate as tracer.
- Author
-
Dressendörfer RA, Heim JM, Gerzer R, and Strasburger CJ
- Subjects
- Biotin chemical synthesis, Biotin chemistry, Biotin isolation & purification, Chromatography, Liquid, Cyclic GMP chemical synthesis, Cyclic GMP chemistry, Cyclic GMP isolation & purification, Reproducibility of Results, Sensitivity and Specificity, Biotin analogs & derivatives, Cyclic GMP analogs & derivatives, Cyclic GMP analysis, Immunoassay methods
- Abstract
2'-O-monosuccinylguanosine 3':5'-cyclic monophosphate was coupled to N-biotinyl-1,8-diamino-3,6-dioxaoctane after converting succinyl-cGMP into its N-hydroxysuccinimide active ester. Isolation and purification of the succinyl-cGMP-biotin conjugate was performed with FPLC using reversed phase chromatography. The synthesis described yielded a conjugate suitable for use as tracer in immunoassays for the cGMP measurement in plasma and urine samples. Employing biotin as the primary probe in a competitive solid phase immunoassay allows for flexible end point determination by means of commercially available labeled streptavidin derivatives. Streptavidin-europium was used in conjunction with the DELFIA-system for time-resolved fluorometric end point measurement (TR-FIA), streptavidin-horseradish peroxidase was used for colorimetric end point determination (EIA). Both non radioactive immunoassay systems showed excellent correlation with the reference radioimmunoassay, good sensitivity and reproducibility. The succinyl-cGMP-biotin conjugate was shown to be stable for more than two years without any apparent loss of chemical stability or immunological reactivity.
- Published
- 1995
- Full Text
- View/download PDF
13. Distribution of membrane bound guanylyl cyclases in human intestine.
- Author
-
Krause G, Bayerl A, Heim JM, Singh S, and Gerzer R
- Subjects
- Adult, Aged, Atrial Natriuretic Factor pharmacology, Bacterial Toxins pharmacology, Base Sequence, Cell Membrane enzymology, Enterotoxins pharmacology, Escherichia coli Proteins, Humans, Intestinal Mucosa enzymology, Intestine, Large enzymology, Intestine, Small enzymology, Middle Aged, Molecular Sequence Data, Peptide Fragments pharmacology, Polymerase Chain Reaction, Restriction Mapping, Guanylate Cyclase metabolism, Intestines enzymology, Isoenzymes metabolism
- Abstract
The quantification and distinction of particulate guanylyl cyclases in the human intestine were considered by an enzymatic approach, which comprised the signal transduction from receptor binding to cGMP formation, and, in addition, by showing the expression of an intracellular portion of these transmembrane proteins. Basal guanylyl cyclase (GC) activities were 50 to 80 pmol cGMP formation/min/mg protein and were stimulated up to twofold by heat stable enterotoxin, but were not significantly influenced by atrial natriuretic factor. Enzymatic analysis of colonoscopic specimens pointed to the prevalence of guanylyl cyclase C in the terminal ileum and in the large bowel including colon ascendens, colon descendens, sigmoid, and rectum. The availability of sequence information on human guanylyl cyclases permitted the development of a polymerase chain reaction approach for distinguishing the expression of GC-A and GC-C in human tissue samples. The expression levels of particulate guanylyl cyclases found by polymerase chain reaction in surgical biopsy specimens confirmed the enzymatic data, in that substantial expression of GC-C was found not only in the small intestine but also in the large bowel. According to the restriction mapping of amplificates, GC-C prevailed over GC-A throughout the human intestine, particularly in the mucosal layers.
- Published
- 1994
- Full Text
- View/download PDF
14. Soluble guanylyl cyclase and platelet function.
- Author
-
Buechler WA, Ivanova K, Wolfram G, Drummer C, Heim JM, and Gerzer R
- Subjects
- Animals, Blood Platelets drug effects, Blood Platelets enzymology, Gene Deletion, Guanylate Cyclase biosynthesis, Guanylate Cyclase genetics, Humans, Transfection, Blood Platelets physiology, Cyclic GMP pharmacology, Guanylate Cyclase blood, Nitric Oxide pharmacology, Vasodilator Agents pharmacology
- Published
- 1994
- Full Text
- View/download PDF
15. Plasma cGMP level as a marker of the hydration state in renal replacement therapy.
- Author
-
Lauster F, Heim JM, Drummer C, Fülle HJ, Gerzer R, and Schiffl H
- Subjects
- Adult, Aged, Atrial Natriuretic Factor blood, Biomarkers, Female, Humans, Male, Middle Aged, Body Water metabolism, Cyclic GMP blood, Peritoneal Dialysis, Continuous Ambulatory, Renal Dialysis
- Abstract
We investigated, whether plasma cyclic guanosine 3':5'-monophosphate (cGMP) may be suited as a marker of hyperhydration in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). In 81 HD patients the levels of atrial natriuretic peptide (ANP) and cGMP were markedly elevated before HD (ANP: 165 +/- 11.1 pg/ml; cGMP 43.5 +/- 2.2 pmol/ml). Significantly lower values (P < 0.01) were found after HD (ANP: 97 +/- 8.4 pmol/ml; cGMP 19.5 +/- 1.5 pmol/ml). Twenty-three patients had cGMP levels above 20 pmol/ml after HD. Therefore "dry body weight" was reduced in these patients. This resulted in a "normalization" of cGMP values to a postdialytic range below 20 pmol/ml in the majority of patients. All seven patients with persistently high cGMP levels despite weight reduction had left sided heart failure. In 33 CAPD patients ANP was slightly lower than after HD (68 +/- 10.4 pg/ml), and the cGMP level (22.4 +/- 2.3 pmol/ml) was between pre- and postdialytic values in HD. In eight CAPD patients with clinical signs of hypervolemia plasma cGMP, but not ANP, was significantly elevated. We conclude that the plasma cGMP level appears to be a reliable marker for fluid overload in patients on renal replacement therapy with normal heart function.
- Published
- 1993
16. The circulating bioactive form of human guanylin is a high molecular weight peptide (10.3 kDa).
- Author
-
Kuhn M, Raida M, Adermann K, Schulz-Knappe P, Gerzer R, Heim JM, and Forssmann WG
- Subjects
- Amino Acid Sequence, Enzyme Activation, Guanylate Cyclase metabolism, Humans, Molecular Sequence Data, Molecular Weight, Natriuretic Peptides, Peptides chemistry, Sequence Alignment, Gastrointestinal Hormones, Peptides blood
- Abstract
Guanylin is a peptide isolated from rat intestine that stimulates intestinal guanylate cyclase. We describe here the purification of circulating guanylin from human hemofiltrate. By N-terminal protein sequence analysis 47 amino acids were determined. This sequence corresponds to the positions 22 to 68 of the prohormone deduced from the cDNA sequence of human proguanylin. Mass spectral analysis of the circulating peptide showed the molecular weight to be 10,336 Da, which corresponds to the mass calculated from position 22 to the C-terminus of the peptide predicted from the cDNA sequence. Circulating guanylin markedly increased the cyclic GMP content of T84 cells. Our data show that the hormonal form of guanylin is circulating as a 10.3-kDa peptide in human blood.
- Published
- 1993
- Full Text
- View/download PDF
17. Plasma ANP and cGMP levels in CAPD patients.
- Author
-
Lauster F, Heim JM, Drummer C, Gerzer R, and Schiffl H
- Subjects
- Adult, Biomarkers blood, Female, Humans, Male, Middle Aged, Renal Dialysis, Water-Electrolyte Imbalance etiology, Atrial Natriuretic Factor blood, Cyclic GMP blood, Peritoneal Dialysis, Continuous Ambulatory adverse effects, Water-Electrolyte Imbalance diagnosis
- Published
- 1993
- Full Text
- View/download PDF
18. Comparison of a cloned ANF-sensitive guanylate cyclase (GC-A) with particulate guanylate cyclase from adrenal cortex.
- Author
-
Heim JM, Singh S, Fülle HJ, and Gerzer R
- Subjects
- Animals, Binding, Competitive, Cattle, Cell Line, Cell Membrane enzymology, Cyclic GMP metabolism, Guanylate Cyclase genetics, Humans, Rats, Receptors, Atrial Natriuretic Factor, Receptors, Cell Surface metabolism, Transfection, Adrenal Cortex enzymology, Atrial Natriuretic Factor pharmacology, Diuretics pharmacology, Guanylate Cyclase metabolism, Neuroglia drug effects, Peptide Fragments pharmacology
- Abstract
Recently, an ANF-sensitive guanylate cyclase (GC-A) has been cloned from a rat brain cDNA library. Here we studied the stimulation of cyclic GMP accumulation in response to atrial natriuretic factor (ANF), urodilatin and atriopeptin I (AP-1) in a rat glioma C6 cell line permanently transfected with GC-A as well as GC-A activity in membranes from these C6 cells and in membranes from COS-7 cells that were transiently transfected with GC-A. We also measured binding affinities for these natriuretic peptides in the membrane preparations. These characteristics of GC-A were compared to those of membrane preparations from adrenal cortex of bovine and human origin. The order of potency of stimulation of cyclic GMP accumulation in permanently transfected glioma cells was ANF greater than urodilatin greater than AP I; AP I stimulated cyclic GMP accumulation. A similar order of potency was obtained for stimulation of guanylate cyclase activity in membranes from permanently transfected glioma cells as well as from transiently transfected COS-7 cells. In contrast, AP-1 was uneffective to stimulate guanylate cyclase in membrane preparations from adrenal cortex from bovine as well as from human origin. Furthermore, urodilatin was equipotent to ANF in these preparations. Binding affinities were comparable for ANF and urodilatin in membranes from cells transfected with GC-A and in membranes from adrenal cortex of both sources, whereas AP-1 had a weaker affinity in all preparations studied.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
19. Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line.
- Author
-
Singh S, Singh G, Heim JM, and Gerzer R
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Cell Line, Colon, Cyclic GMP metabolism, DNA isolation & purification, Gene Library, Guanylate Cyclase metabolism, Humans, Kinetics, Molecular Sequence Data, RNA genetics, RNA isolation & purification, Rats, Receptors, Cell Surface metabolism, Receptors, Enterotoxin, Receptors, Guanylate Cyclase-Coupled, Sequence Homology, Nucleic Acid, Transfection, DNA genetics, Guanylate Cyclase genetics, Receptors, Cell Surface genetics, Receptors, Peptide
- Abstract
Heat stable enterotoxins (STs) are low molecular-weight peptides secreted by enterotoxigenic bacteria. One type of these enterotoxins (STa) induces intestinal secretion leading to acute diarrhea by binding to a membrane form of guanylate cyclase. We have isolated a cDNA from a human colonic cell line, T84, encoding for a guanylate cyclase-coupled enterotoxin receptor (STaR). The predicted amino acid sequence of the human STa receptor is 81% identical with the previously cloned enterotoxin receptor (GC-C) from rat intestine. COS-7 cells transiently transfected with the cloned cDNA expressed specific concentration-dependent response to STa as measured by cyclic GMP accumulation and is about 20 times more sensitive to the stimulation by STa than has been shown for GC-C.
- Published
- 1991
- Full Text
- View/download PDF
20. Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers.
- Author
-
Drummer C, Valta-Seufzer U, Karrenbrock B, Heim JM, and Gerzer R
- Subjects
- Adult, Bleeding Time, Cyclic GMP blood, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Isosorbide Dinitrate blood, Isosorbide Dinitrate pharmacology, Male, Molsidomine blood, Platelet Activating Factor pharmacology, Random Allocation, Reference Values, Thromboxane B2 blood, Isosorbide Dinitrate analogs & derivatives, Molsidomine pharmacology, Platelet Aggregation Inhibitors
- Abstract
The purpose of the present work was to investigate the ex vivo platelet-inhibiting properties of the nitric oxide-containing vasodilator, molsidomine, and the organic nitrate, isosorbide-5-mononitrate, in comparison with placebo. Ex vivo platelet aggregation in 11 healthy volunteers was measured before, as well as 30 and 60 min after, the intake of either 4 mg molsidomine, 20 mg isosorbide-5-mononitrate (ISMN) or placebo in a randomized double-blind fashion. The release of thromboxane was also determined. Threshold doses of platelet-activating factor (PAF) to induce irreversible aggregation were significantly increased by 100 and 120% 30 and 60 min after molsidomine. Slopes of aggregation curves (aggregation induced with 50 and 200 nM PAF) were significantly reduced after molsidomine (P less than 0.01). Small platelet-inhibiting effects were also observed after ISMN and after placebo intake. The release of thromboxane was not influenced when platelets were maximally stimulated either during clotting of whole blood or during aggregation of platelet-rich plasma with a high dose of PAF. Thromboxane release with a low dose of PAF was reduced 30 and 60 min after drug intake, independent of whether molsidomine, ISMN or placebo was applied. The data indicate that the usual clinical doses of molsidomine, but not of ISMN inhibit platelet aggregation in healthy man.
- Published
- 1991
- Full Text
- View/download PDF
21. Functional modulation of ANF-sensitive particulate guanylate cyclase by redox mechanisms.
- Author
-
Fülle HJ, Heim JM, and Gerzer R
- Subjects
- Adrenal Cortex drug effects, Animals, Atrial Natriuretic Factor metabolism, Cattle, Cyclic GMP metabolism, Guanosine Triphosphate metabolism, In Vitro Techniques, Kinetics, Oxidation-Reduction, Rats, Signal Transduction drug effects, Sulfhydryl Compounds pharmacology, Adrenal Cortex enzymology, Atrial Natriuretic Factor pharmacology, Guanylate Cyclase metabolism
- Abstract
We examined the effects of sulfhydryl-reactive redox agents and of the apparent oxidation-reduction (redox) potential of the assay medium on enzyme activity and atrial natriuretic factor (ANF) binding properties of particular guanylate cyclase from bovine adrenal cortex. Redox potential was varied by addition of redox-reactive agents and quantified by electrochemical measurement. The modification of free SH groups by thiol-reactive agents had only a minor effect on ANF binding or on the extent of ANF-dependent enzyme stimulation whereas free thiol groups were essential for basal enzyme activity of ANF-sensitive particulate guanylate cyclase. Basal and ANF-stimulated particulate guanylate cyclase activity was modulated by exposure to different redox potential states. This modulation was different for the substrates Mg.GTP and Mn.GTP. The apparent redox potential had no influence on the extent of guanylate cyclase activation by ANF. Our results suggest that critical free thiol groups, which are sensitive to thiol-reactive redox agents, are involved in the catalytic, but not in the receptor function of ANF-sensitive particulate guanylate cyclase. These thiol groups could be the structural basis for the effects of redox events which modulate basal enzyme activity, but not activation by ANF.
- Published
- 1991
- Full Text
- View/download PDF
22. [Platelet aggregation with SIN 1: comparison with isosorbide-5-mononitrate and acetylsalicylic acid].
- Author
-
Gerzer R, Karrenbrock B, Niederreiter B, Heim JM, and Drummer C
- Subjects
- Dose-Response Relationship, Drug, Humans, Isosorbide Dinitrate pharmacology, Molsidomine pharmacology, Aspirin pharmacology, Isosorbide Dinitrate analogs & derivatives, Molsidomine analogs & derivatives, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors pharmacology, Vasodilator Agents pharmacology
- Abstract
SIN 1, the bioactive metabolite of molsidomine, not only appears to lack the problem of inducing nitrate tolerance, but also exerts antiaggregatory and fibrinolytic properties. These effects, which either are not or only in part shared by the drug isosorbide-5-mononitrate, might be beneficial in the prevention of thromboembolic complications in cardiovascular disease. In contrast to the effects of acetylsalicylic acid, SIN 1 already inhibits aggregation during the first phase of aggregation, and it inhibits aggregations induced by agonists that are not or only marginally influenced by acetylsalicylic acid (such as the aggregation induced by platelet activating factor). Thus, the antiaggregatory effects of molsidomine cannot replace the effects of acetylsalicylic acid, while a combination of both drugs might be of benefit in the treatment of patients with cardiovascular disease.
- Published
- 1991
23. Kinetic characterization of atrial natriuretic factor-sensitive particulate guanylate cyclase.
- Author
-
Ivanova K, Heim JM, and Gerzer R
- Subjects
- Adrenal Cortex drug effects, Adrenal Cortex enzymology, Adrenal Cortex metabolism, Amiloride pharmacology, Animals, Cattle, Guanylate Cyclase antagonists & inhibitors, In Vitro Techniques, Kinetics, Magnesium pharmacology, Manganese pharmacology, Membranes drug effects, Membranes metabolism, Octoxynol, Polyethylene Glycols pharmacology, Rats, Atrial Natriuretic Factor pharmacology, Guanylate Cyclase metabolism
- Abstract
The present investigation describes kinetic characteristics of membrane-bound and Triton X-100-solubilized atrial natriuretic factor (ANF)-sensitive guanylate cyclase from bovine adrenal cortex. The kinetic analysis of both enzyme forms suggests that in the presence of manganese, ANF induces or stabilizes at least two apparent GTP*Mn2(+)- and in addition two Mn2(+)-binding sites. Addition of the natriuretic drug amiloride favors this state. ATP increases the vmax in the presence of ANF for GTP*Mg2+, but not for GTP*Mn2+ as a substrate. With GTP*Mg2+, amiloride has no effect on basal or ANF-stimulated activity, but slightly reduces the effect of ATP. Under all conditions tested, the enzyme follows regular Michaelis-Menten kinetics in the presence of Mg2+ and exhibits positive cooperativity with Mn2+. Positive cooperativity is also retained after Triton extraction. The results indicate that Triton extraction has no major influence on the kinetic properties of particulate guanylate cyclase when the extraction procedure is done carefully. The data also support the suggestion that multiple interactions of subunits might occur upon activation of the enzyme by ANF in the presence of Mn2+.
- Published
- 1990
- Full Text
- View/download PDF
24. Effects of a small bolus dose of ANF in healthy volunteers and in patients with volume retaining disorders.
- Author
-
Heim JM, Gottmann K, Weil J, Schiffl H, Lauster F, Loeschke K, and Gerzer R
- Subjects
- Adult, Aged, Atrial Natriuretic Factor blood, Blood Platelets metabolism, Cyclic GMP blood, Female, Hemodynamics drug effects, Humans, Kidney Failure, Chronic therapy, Male, Middle Aged, Receptors, Atrial Natriuretic Factor, Receptors, Cell Surface blood, Recombinant Proteins administration & dosage, Water-Electrolyte Balance drug effects, Atrial Natriuretic Factor administration & dosage, Heart Failure therapy, Liver Cirrhosis therapy
- Abstract
Thirty-seven patients with volume-retaining disorders (liver cirrhosis with ascites, n = 8; heart failure NYHA III-IV, n = 12; endstage renal failure, n = 17) and twelve healthy age-matched controls were given a small dose (33 micrograms) of hANF (human atrial natriuretic factor). We tested the resulting hemodynamic and renal effects as well as the effect on plasma cyclic GMP levels and compared them with the properties of platelet ANF receptors. The ANF injection evoked an increase in cyclic GMP plasma levels of 19.3 +/- 2.2 nM in healthy controls. This increase tended to be smaller in the cirrhosis group (15.5 +/- 3.3 nM) and in the heart failure group (16.8 +/- 2.3 nM) than in the dialysis group (20.5 +/- 2.5 nM). The invasion rates of cyclic GMP were comparable in all groups, but the evasion rates increased more in the heart failure and endstage renal failure groups (27.9 +/- 7.7 min and 26.1 +/- 3.4 min, respectively) than in the cirrhosis and control groups (14.9 +/- 1.9 min and 14.2 +/- 1.9 min, respectively). Patients with endstage renal failure and congestive heart failure showed a smaller decrease in diastolic blood pressure than controls and patients with liver cirrhosis. Renal actions of ANF were diminished in cirrhosis and heart failure patients. Binding capacities of platelet ANF receptors were higher in the control group (12.2 +/- 1.5 receptors/cell) than in the patient groups (cirrhosis, 7.8 +/- 1.2; endstage renal failure, 8.0 +/- 0.9; heart insufficiency, 8.0 +/- 1.0 receptors/cell), with no differences among the patient groups. Binding affinities were not significantly different. Correlation analysis showed that the relationship between the actions of ANF and the increases in plasma cyclic GMP levels is loose and cannot predict the hemodynamic or renal effects of exogenous ANF in a given patient. Although the behavior of plasma cyclic GMP levels fails to predict the responsiveness of the body to ANF in a given patient, it does reflect the differences between the patient groups and the control group. In contrast, we found no correlation between the properties of platelet ANF receptors and ANF action.
- Published
- 1990
- Full Text
- View/download PDF
25. Effect of molsidomine on ex vivo platelet aggregation and plasma guanosine 3':5'-cyclic monophosphate levels in healthy volunteers.
- Author
-
Karrenbrock B, Heim JM, and Gerzer R
- Subjects
- Adult, Female, Humans, Male, Molsidomine analogs & derivatives, Molsidomine pharmacokinetics, Vasodilator Agents pharmacokinetics, Vasodilator Agents pharmacology, Cyclic GMP blood, Molsidomine pharmacology, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors pharmacology, Prodrugs
- Abstract
To find out whether 3-morpholino-sydnonimine (SIN 1), the active metabolite of molsidomine, exerts its antiaggregatory effects not only in vitro but also in vivo, we tested ex vivo aggregation before and after intravenous application of molsidomine in healthy volunteers. We also measured plasma levels of guanosine 3':5'-cyclic monophosphate (cyclic GMP) as SIN 1, the bioactive metabolite of molsidomine, becomes effective via activation of soluble guanylate cyclase. In eight out of ten subjects molsidomine had an inhibitory effect on platelet aggregation and a higher threshold concentration of platelet-activating factor was required after molsidomine application to induce irreversible aggregation. Despite the effect on platelets, plasma cyclic GMP levels did not increase. These results suggest that the nitric oxide-containing SIN 1 inhibits platelet aggregation not only in vitro but also in vivo and that this property can be a beneficial effect in antianginal therapy.
- Published
- 1990
- Full Text
- View/download PDF
26. [Inhibition of platelet aggregation by endothelium-derived relaxing factor-like agents].
- Author
-
Gerzer R, Karrenbrock B, Drummer C, and Heim JM
- Subjects
- Animals, Humans, Isosorbide Dinitrate analogs & derivatives, Isosorbide Dinitrate therapeutic use, Molsidomine analogs & derivatives, Platelet Aggregation Inhibitors pharmacology, Vasodilator Agents therapeutic use, Coronary Circulation drug effects, Molsidomine therapeutic use, Nitric Oxide physiology, Platelet Aggregation drug effects
- Abstract
In the last years, an inhibition of aggregation by organic nitrates or by similar drugs has been demonstrated by some authors, but has also been ruled out by other authors. The present work was thus performed to study a possible inhibition of platelet aggregation by the respective drugs in comparison with the molecular mechanism of action of these drugs, that is activation of soluble guanylate cyclase. We found that in vitro, organic nitrates activate soluble guanylate cyclase and inhibit platelet aggregation only in millimolar concentrations, while sodium nitroprusside and SIN-1, the active metabolite of molsidomine, influence these parameters in micromolar concentrations. This difference between the actions of the O-NO2-containing nitrates and the NO-containing compounds nitroprusside and SIN-1 is, however, not apparent ex vivo. Ex vivo, not only molsidomine, that is converted in the liver to SIN-1, but also isosorbide-5-mononitrate inhibited platelet aggregation. Thus, it appears that organic nitrates can in vivo release nitric oxide in a tissue other than platelets in amounts that are high enough to inhibit platelet aggregation. These studies suggest, that an antiaggregatory effect may participate in the clinical actions not only of drugs that directly resemble EDRF, such as SIN-1, but also by the organic nitrates. However, since nitrates cannot be activated directly by the platelets, it appears that also the antiaggregatory effects of nitrates, but not of molsidomine, underlie the mechanisms of tolerance development.
- Published
- 1990
27. Influence of diurnal rhythm, posture and right atrial size on plasma atrial natriuretic peptide levels.
- Author
-
Weil J, Strom TM, Heim JM, Lang RE, Schindler M, Haufe M, Vogel M, and Gerzer R
- Subjects
- Adult, Cyclic GMP blood, Heart Defects, Congenital blood, Humans, Infant, Male, Posture, Reference Values, Atrial Natriuretic Factor blood, Circadian Rhythm, Heart Atria anatomy & histology
- Abstract
A diurnal rhythm of plasma atrial natriuretic peptide (ANP) and cyclic 3'5'guanosine monophosphate (cGMP) was found in nine healthy adult volunteers. Significantly higher levels of both parameters were found in the morning (8 a.m.) than later during the day and night (p less than 0.05). Different postures had only a little influence on plasma ANP and cGMP levels in seven healthy adult volunteers using a tilt table. Tilted from supine into upright, head-down (-20 degrees) and then again into supine posture, significant differences of both parameters were only found between levels shortly after the end of the upright posture and those at the end of the head-down posture (p less than 0.05). Furthermore, in infants with various congenital heart diseases (n = 19) and control infants (n = 35) the right atrial area was determined by two-dimensional echocardiography and related to plasma ANP levels. Out of 19 infants with cardiac disease, 11 showed an enlarged right atrial area (i.e. above the 95th percentile in the range of control infants). All these 11 infants also had higher plasma ANP levels (range 115-670 pg/ml) than the healthy infants (range 5-98 pg/ml). These data support the assumption that atrial wall distension seems to be a stimulus for ANP release.
- Published
- 1988
28. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity.
- Author
-
Gerzer R, Karrenbrock B, Siess W, and Heim JM
- Subjects
- Adult, Blood Platelets enzymology, Enzyme Activation drug effects, Humans, In Vitro Techniques, Molsidomine analogs & derivatives, Molsidomine pharmacology, Nitroprusside pharmacology, Platelet Aggregation drug effects, Solubility, Blood Platelets drug effects, Guanylate Cyclase blood, Nitrates pharmacology
- Abstract
We have directly compared the effects of the nitrates isosorbide-5-mononitrate, nitroglycerin and isosorbide dinitrate and of the nitric oxide-containing sodium nitroprusside and 3-morpholino-sydnonimine (SIN 1) as well as of the bioinactive precursor of SIN 1, molsidomine, on platelet activating factor-induced platelet aggregation and activation of soluble guanylate cyclase. The effects of these agents on the aggregation and on soluble guanylate cyclase activity of human platelets were closely correlated. Whereas nitroprusside and SIN 1 were very potent inhibitors of aggregation and activators of soluble guanylate cyclase in micromolar concentrations, the other drugs were effective only at millimolar concentrations. Preincubation of platelets with cysteine did not or only slightly increase the ability of isosorbide-5'-mononitrate and isosorbide dinitrate to inhibit aggregation, but a clear increase was observed after preincubation with nitroglycerin. These data support the concept that cyclic GMP is the mediator of nitric oxide-induced inhibition of platelet aggregation and indicate that nitrates cannot directly inhibit aggregation or be converted to nitric oxide-containing agents by a specific mechanism in platelets. The data also suggest that SIN 1 and nitroprusside, but not or only to a certain degree the nitrates, can be considered as exogenous endothelium-derived relaxing factors.
- Published
- 1988
- Full Text
- View/download PDF
29. Effects of clonidine and dihydralazine on plasma ANF and cyclic GMP levels in humans during volume loading.
- Author
-
Müller T, Heim JM, Weil J, Wehling M, Witzgall H, and Gerzer R
- Subjects
- Adult, Blood Pressure, Cyclic GMP urine, Heart Rate, Hematocrit, Humans, Infusions, Intravenous, Isotonic Solutions, Male, Potassium urine, Sodium urine, Sodium Chloride administration & dosage, Atrial Natriuretic Factor blood, Clonidine pharmacology, Cyclic GMP blood, Dihydralazine pharmacology, Hydralazine analogs & derivatives
- Abstract
Acute volume loading increases plasma atrial natriuretic factor (ANF) levels in man and animals. In the present work we have compared the effects of a 1-week oral application of clonidine (2 x 0.075 mg/day) to dihydralazine (2 x 25 mg/day) in eight healthy volunteers on changes in plasma ANF and plasma and urine cyclic GMP levels after acute volume loading with 2 I physiological saline i.v. Basal plasma ANF levels before infusion were decreased by clonidine to 65% of the untreated controls and remained unaltered with dihydralazine. Volume loading increased plasma ANF levels by about 40% in the control and 30% in the dihydralazine treated group, whereas plasma ANF remained unchanged by volume loading in the clonidine-treated group. Dihydralazine increased basal cyclic GMP levels and urinary cyclic GMP excretion by 30 and 90%, respectively. Basal cyclic GMP levels were identical without treatment and after clonidine treatment. Saline infusion increased cyclic GMP levels by 40% in the control and clonidine-treated groups, and by 25% in the dihydralazine-treated group. Urinary cyclic GMP excretion increased by 2.1-, 1.6-, and 1.2-fold, respectively, in the controls, after clonidine, or after dihydralazine. The results of this study suggest that ANF is involved in the hormonal and hemodynamic effects that are induced by clonidine, but not in those induced by dihydralazine.
- Published
- 1987
30. Binding sites for atrial natriuretic peptide on platelets in patients with congestive cardiomyopathy.
- Author
-
Strom TM, Weil J, Braun F, Stangl K, Timnik A, Heim JM, and Gerzer R
- Subjects
- Aged, Binding Sites, Cyclic GMP blood, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Radioimmunoassay, Time Factors, Atrial Natriuretic Factor metabolism, Blood Platelets metabolism, Cardiomyopathy, Dilated metabolism
- Abstract
The aim of the present investigation was to evaluate a possible down-regulation of atrial natriuretic peptide (ANP) binding sites on platelets in patients with chronically elevated ANP plasma levels. The assay procedure was proved to be able to measure the total number of binding sites even in the presence of high ANP plasma levels. We studied 15 adult patients with congestive cardiomyopathy in comparison to 18 healthy volunteers. In the patients the median ANP plasma level (median = 375, range: 155-900 pg ml-1) was about six-fold higher than in the healthy volunteers (median: 55.5, range: 20-90 pg ml-1). The median cyclic guanosine monophosphate (cGMP) plasma level (median: 6.2, range: 2.5-21.4 pmol ml-1) was about three-fold higher than in the healthy volunteers (median: 1.8 range: 1-2.8 pmol ml-1). Despite these markedly elevated ANP and cGMP plasma levels we did not find significantly less receptors per platelet in the patients (median: 19, range: 7.2-60.2) than in the healthy volunteers (median: 24.5, range: 14.8-41.1). Furthermore, there was no difference in the dissociation constants between the patients (median: 10.5, range: 7.9-27.4 pmol l-1) and the control subjects (median: 8.9, range: 5.4-17 pmol l-1).
- Published
- 1988
- Full Text
- View/download PDF
31. Is cyclic GMP a clinically useful marker for ANF action?
- Author
-
Heim JM, Gottmann K, Weil J, Haufe MC, and Gerzer R
- Subjects
- Atrial Natriuretic Factor pharmacology, Atrial Natriuretic Factor physiology, Cyclic GMP physiology, Cyclic GMP urine, Edetic Acid, Humans, Indicators and Reagents, Models, Theoretical, Reference Values, Atrial Natriuretic Factor blood, Cyclic GMP blood
- Abstract
The action of ANF is, at least in part, mediated by the activation of particulate guanylate cyclase. Increases in plasma ANF levels induce a marked increase in the plasma levels and urinary excretion of cyclic GMP. In contrast to agents that stimulate particulate guanylate cyclase, activators of soluble guanylate cyclase, such as the bioactive molsidomine metabolite, SIN 1, induce only a modest, not significant, increase in plasma cyclic GMP levels. Thus, increases in plasma cyclic GMP levels appear to be specific for the activation of particulate guanylate cyclase. Cyclic GMP is stable in whole blood in the presence of EDTA and can easily be measured in plasma and urine. It may therefore be a valuable alternative for ANF measurement in the clinical routine. In contrast to urinary ANF excretion, the urinary excretion of cyclic GMP sensitively reflects increases in plasma ANF levels. Measurement of cyclic GMP excretion may therefore be an alternative for plasma ANF and plasma cyclic GMP measurement especially in situations where blood drawing is difficult, e.g. in newborns. Measurement of basal cyclic GMP followed by determination of increases in cyclic GMP levels after injection of a small ANF bolus dose tests the cellular sensitivity to ANF. This may give further insight in the mechanism of the regulation of ANF effects. Therefore, cyclic GMP in many cases appears to be a sensitive marker for the action of ANF in man.
- Published
- 1988
32. [Hemodynamic and medicamentous modification of stimulated atrial natriuretic factor secretion].
- Author
-
Haufe MC, Weil J, Heim JM, Ernst JE, Gerzer R, and Theisen K
- Subjects
- Adult, Aged, Blood Pressure drug effects, Cardiac Catheterization, Coronary Disease blood, Cyclic GMP blood, Female, Humans, Male, Middle Aged, Atenolol therapeutic use, Atrial Natriuretic Factor blood, Cardiac Pacing, Artificial, Coronary Disease drug therapy, Molsidomine therapeutic use, Verapamil therapeutic use
- Abstract
The secretion of atrial natriuretic factor (ANF) and its adaptation to pharmacologic and hemodynamic interventions were investigated in 36 patients with sinus rhythm. To provoke standardized secretion of ANF all patients underwent two periods of rapid right ventricular pacing for 4 min with a 15 min interval. Immediately after the first pacing eight patients received 5 mg verapamil, 10 patients 5 mg atenolol and 10 patients 4 mg molsidomine intravenously. Eight patients remained untreated and served as controls. The amounts of atrial pressure increments due to pacing were identical (70% over basal pressure) in all patients. After molsidomine, but not after the other drugs, basal right atrial pressure was lowered. In controls the secretion of ANF due to the second stimulation was significantly (2.5-fold) larger than the secretion induced by the first stimulation. In patients receiving verapamil the secretion response after the second pacing was blunted. Atenolol did not affect the release of ANF. After molsidomine the upward regulation of the ANF secretion rate - seen in controls - was abolished. Thus, the myoendocrine cells are capable for a fast upward regulation of their ANF secretion rate after repeated stimuli. Verapamil directly blocks stimulated ANF secretion, whereas beta-blockade shows no effect. Molsidomine seems to impair enhanced ANF release by lowering basal atrial pressure.
- Published
- 1989
33. The role of hemoglobin in generating oxyradicals.
- Author
-
Rifkind JM, Zhang L, Heim JM, and Levy A
- Subjects
- Catalase metabolism, Cytochrome c Group blood, Humans, Kinetics, Oxygen blood, Partial Pressure, Erythrocytes metabolism, Hemoglobins metabolism, Superoxides blood
- Published
- 1988
- Full Text
- View/download PDF
34. Cellular mechanisms of action of atrial natriuretic factor.
- Author
-
Gerzer R, Heim JM, Schütte B, and Weil J
- Subjects
- Adenylyl Cyclase Inhibitors, Animals, Atrial Natriuretic Factor pharmacology, Biomechanical Phenomena, Calcium antagonists & inhibitors, Cyclic GMP metabolism, Cyclic GMP physiology, Enzyme Activation drug effects, Guanylate Cyclase metabolism, Humans, Phosphorylation, Proteins metabolism, Atrial Natriuretic Factor physiology, Cell Physiological Phenomena
- Abstract
Atrial natriuretic factor (ANF) interacts with its target cells through specific receptors. This interaction induces, in most cell types, the activation of particulate guanylate cyclase and decreased Calcium mobilisation. In addition, ANF also decreases adenylate cyclase activity in some tissues. Activation of particulate guanylate cyclase, and additionally inhibition of adenylate cyclase, appear to initiate the cellular responses to circulating ANF. The activation of particulate guanylate cyclase is tissue-specific, immediate and can be demonstrated also on the solubilized enzyme. The ANF receptor appears to be tightly coupled to particulate guanylate cyclase. The increased formation of cyclic GMP induces cGMP-dependent protein phosphorylation in target cells. In addition, cyclic GMP inhibits Calcium mobilisation in several tissues. This may explain observations of inhibition of Calcium mobilisation after ANF. Cyclic GMP is not only degraded by phosphodiesterase, but is also extruded from target cells. As a consequence of cGMP extrusion, ANF increases the levels of cyclic GMP in plasma and urine in animals and man. Cyclic GMP is also increased in various disease states, in which ANF is increased. In contrast, cyclic AMP plasma levels are unaltered after ANF elevations. At present, the exact mechanisms, by which cellular functions are altered by ANF are still incompletely understood. It is anticipated, that the close correlation between the cyclic GMP system and effects of ANF in various target tissues is a key finding that will help elucidate the exact mechanisms of ANF action.
- Published
- 1987
35. Effects of a bolus dose of atrial natriuretic factor in young and elderly volunteers.
- Author
-
Heim JM, Gottmann K, Weil J, Strom TM, and Gerzer R
- Subjects
- Adult, Aged, Blood Platelets metabolism, Blood Pressure drug effects, Calcium urine, Cyclic GMP blood, Cyclic GMP urine, Female, Heart Rate drug effects, Humans, Injections, Intravenous, Male, Middle Aged, Receptors, Atrial Natriuretic Factor, Receptors, Cell Surface metabolism, Sodium urine, Atrial Natriuretic Factor pharmacology, Gingiva, Hemodynamics drug effects, Kidney drug effects
- Abstract
We assessed the haemodynamic and renal effects as well as the effects on plasma cGMP levels of a small i.v. dose (33 micrograms) of human atrial natriuretic factor (99-126; hANF) in two age groups of healthy volunteers. Binding properties of platelet ANF receptors were also measured. The elderly (four males, eight females, mean age 52.3 years) showed increased haemodynamic (decrease in blood pressure) and renal responses (diuresis, natriuresis, calciuresis) as well as greater increases in plasma cGMP levels and urinary cGMP excretion than the young subjects (four males, 12 females, mean age 26 years). Binding capacities and affinities of platelet ANF receptors were identical in both groups. These data indicate that the sensitivity to ANF increases with age and that this increased sensitivity is reflected in the reactivity of plasma cGMP levels but not in the properties of platelet ANF receptors. The data may be important for the therapeutic use of ANF, for the understanding of the physiological regulation of ANF action and may underline the necessity of using age-matched control subjects for clinical studies on the possible therapeutic effectiveness of ANF.
- Published
- 1989
- Full Text
- View/download PDF
36. Cooperative disordering of single-stranded polynucleotides through copper crosslinking.
- Author
-
Rifkind JM, Shin YA, Heim JM, and Eichhorn GL
- Subjects
- Binding Sites, Phosphates, Poly A, Poly C, Protein Binding, Copper, Nucleic Acid Conformation, Polynucleotides
- Published
- 1976
- Full Text
- View/download PDF
37. Amiloride increases the sensitivity of particulate guanylate cyclase to atrial natriuretic factor.
- Author
-
Heim JM, Ivanova K, and Gerzer R
- Subjects
- Amiloride analogs & derivatives, Animals, Cattle, Cyclic GMP biosynthesis, Dose-Response Relationship, Drug, Guanosine Triphosphate metabolism, Ion Channels drug effects, Kinetics, Sodium metabolism, Amiloride pharmacology, Atrial Natriuretic Factor pharmacology, Guanylate Cyclase metabolism
- Abstract
The natriuretic agent amiloride induces a shift of the dose-response curve of particulate guanylate cyclase to atrial natriuretic factor (ANF) to the left. The ANF concentration for half-maximal activation of guanylate cyclase is shifted from 20 to 3 nM in the presence of 100 microM amiloride. This effect is observed with GTP*Mn2+, but not with GTP*Mg2+ as substrate. Amiloride derivatives, which inhibit a specific Na+-channel, also shift the dose-response curve to the left. These data suggest that some of the effects of amiloride may be mediated by an increased sensitivity of particulate guanylate cyclase to ANF.
- Published
- 1988
- Full Text
- View/download PDF
38. Interaction of zinc and hemoglobin: binding of zinc and the oxygen affinity.
- Author
-
Rifkind JM and Heim JM
- Subjects
- Diphosphoglyceric Acids, Hemoglobins, Abnormal, Humans, Hydrogen-Ion Concentration, Kinetics, Partial Pressure, Protein Binding, Hemoglobins, Oxygen blood, Zinc
- Abstract
Stripped human hemoglobin was shown to have a high apparent zinc association constant of 1.3 X 10(7) M-1 with a stoichiometry of one zinc for every two hemes. The saturation of this site produces a dramatic 3.7-fold increase in the oxygen affinity. The effect of zinc on the oxygen affinity is interrelated with the interaction of 2,3-diphosphoglyceric acid (2,3-DPG) and hemoglobin. Thus, a smaller zinc effect is observed in the presence of added 2,3-DPG. Information about the location of the zinc-binding site responsible for the increased oxygen affinity has been obtained by comparing the binding of zinc to various hemoglobins. Blocking the beta93 sulfhydryl group decreases the apparent zinc association constant by an order of magnitude. The substitution of histidine-beta143 in hemoglobin Abruzzo [beta143 (H21) His leads to Arg] and hemoglobin Little Rock [beta143 (H21) His leads to Gln] decreases the apparent zinc association constant by two orders of magnitude. The substitution of histidine-beta143 by other amino acids and the reaction of the beta93 sulfhydryl group are known to produce dramatic increases in the oxygen affinity. The binding of zinc to one or both of these amino acids can, therefore, explain the zinc-induced increase in the oxygen affinity.
- Published
- 1977
- Full Text
- View/download PDF
39. Effects of clonidine and dihydralazine on atrial natriuretic factor and cGMP in humans.
- Author
-
Wehling M, Müller T, Heim JM, Lorenz R, Witzgall H, Weil J, and Gerzer R
- Subjects
- Adult, Aldosterone blood, Cyclic GMP urine, Diuresis drug effects, Hemodynamics drug effects, Humans, Male, Natriuresis drug effects, Renin blood, Atrial Natriuretic Factor blood, Clonidine pharmacology, Cyclic GMP blood, Dihydralazine pharmacology, Hydralazine analogs & derivatives
- Abstract
The effects of a 1-wk treatment with clonidine (75 micrograms/day twice a day) and dihydralazine (25 mg/day twice a day) on base-line levels of plasma atrial natriuretic factor (ANF) and plasma and urinary guanosine 3',5'-cyclic monophosphate (cGMP) and their changes by acute saline infusion (2 liters) in eight normal subjects were evaluated. Basal ANF was decreased to 65% in the clonidine group compared with both the control and dihydralazine groups. Volume loading increased plasma ANF levels by 30-40% of base-line values in the control and the dihydralazine groups and by 15% in the clonidine group. Basal plasma and urinary cGMP levels were raised by 30 and 90% in the dihydralazine group compared with both other groups. Volume loading increased plasma cGMP levels by 40% in the control and clonidine-treated groups and by 25% in the dihydralazine-treated group. It is concluded that ANF may contribute to hemodynamic effects of clonidine but not to those of dihydralazine. Dihydralazine increases plasma and urinary cGMP, supposedly by direct activation of the soluble guanylate cyclase.
- Published
- 1989
- Full Text
- View/download PDF
40. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.
- Author
-
Gerzer R, Drummer C, Karrenbrock B, and Heim JM
- Subjects
- Enzyme Activation drug effects, In Vitro Techniques, Nitric Oxide metabolism, Platelet Aggregation Inhibitors pharmacology, Cyclic GMP metabolism, Molsidomine analogs & derivatives, Molsidomine pharmacology, Nitrates pharmacology, Platelet Activating Factor physiology, Platelet Aggregation drug effects, Vasodilator Agents pharmacology
- Abstract
We compared in vitro the effects of molsidomine, its active metabolite SIN-1, sodium nitroprusside, and the organic nitrates nitroglycerin, isosorbide-5-mononitrate, and isosorbide-2,5-dinitrate on platelet aggregation induced by platelet activating factor and on the activity of soluble guanylate cyclase. In addition, the effects of molsidomine and of isosorbide-5-mononitrate on ex vivo platelet function were studied. In vitro, SIN-1 and sodium nitroprusside were about 100-fold more potent activators of platelet guanylate cyclase and inhibitors of platelet activating factor-induced aggregation than the other agents. In contrast, in ex vivo experiments, not only molsidomine but also isosorbide-5-mononitrate inhibited platelet activating factor-induced aggregation. These data indicate that molsidomine, SIN-1, and organic nitrates can in vivo, like endothelium-derived relaxing factor, inhibit platelet aggregation and exert antithrombotic properties, although nitrates apparently cannot be converted in platelets to active metabolites. Since the antiaggregatory properties are observed when platelet activating factor is used as an aggregant, and since platelet activating factor-induced aggregation is only weakly influenced by inhibitors of cyclo-oxygenase, this effect might be useful clinically.
- Published
- 1989
41. Urodilatin and beta-ANF: binding properties and activation of particulate guanylate cyclase.
- Author
-
Heim JM, Kiefersauer S, Fülle HJ, and Gerzer R
- Subjects
- Adrenal Glands physiology, Animals, Atrial Natriuretic Factor ultrastructure, Binding, Competitive, Blood Platelets metabolism, Cattle, Enzyme Activation, Humans, In Vitro Techniques, Rats, Receptors, Atrial Natriuretic Factor, Structure-Activity Relationship, Atrial Natriuretic Factor physiology, Guanylate Cyclase metabolism, Peptide Fragments physiology, Receptors, Cell Surface physiology
- Abstract
Urodilatin (ANF-(95-126] and beta-ANF, the antiparallel dimer of ANF-(99-126), are naturally occurring members of the ANF family. We studied their receptor binding properties in human platelets and Triton-solubilized membranes from bovine adrenal cortex and their ability to activate particulate guanylate cyclase in bovine adrenal cortex. In human platelets containing R2-receptors not coupled to particulate guanylate cyclase urodilatin binds with similar affinity as ANF-(99-126) (KD: 55 pM), whereas beta-ANF has an affinity lower than the truncated ANF-(103-123) (KD: 295 pM and 154 pM). Scatchard analysis indicates one binding site for urodilatin as well as for beta-ANF. In adrenal cortex containing predominantly R1-receptors coupled to particulate guanylate cyclase, urodilatin binds with a higher affinity (KD: 30 pM) than ANF-(99-126) (KD: 52 pM) and stimulates to a similar extent to ANF-(99-126) (about two fold at 1 muM), whereas beta-ANF has a smaller affinity (KD: 120 pM) and stimulates particulate guanylate cyclase to a lower extent than ANF-(99-126). The data from platelets and adrenal cortex show that beta-ANF has low binding affinities but stimulates particulate guanylate cyclase, whereas urodilatin appears to be a physiological R1-agonist.
- Published
- 1989
- Full Text
- View/download PDF
42. The effect of divalent ions on the isolation of proteins from rat liver nucleoprotein.
- Author
-
von Hahn HP, Heim JM, and Eichhorn GL
- Subjects
- Amino Acids analysis, Animals, Arginine isolation & purification, Cell Nucleus, Chromatography, Gel, DNA, Edetic Acid, Female, Liver cytology, Liver drug effects, Nucleoproteins analysis, Proteins isolation & purification, Rats, Sodium Chloride, Liver analysis, Magnesium pharmacology, Manganese pharmacology, Nucleoproteins isolation & purification
- Published
- 1970
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.